BioAxone BioSciences Announces Notice of Allowance for Self-Delivering RNA Interference for the Treatment of Spinal Cord Injury – Business Wire

BioAxone BioSciences, Inc., a biotechnology company applying an innovative understanding of axon regeneration and neuronal signaling to transform the lives of patients afflicted with neurotrauma or neurovascular disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO). The notice covers the critical patent application (US 16/321,229) for the proprietary method of treatment of spinal cord injury with BA-434, a novel sd-rxRNA compound that targets transient, non-permanent PTEN suppression to promote axon regeneration and reduce paralysis.

Scientists have provided evidence that suppression of the protein PTEN is one of the most robust targets to promote regeneration of damaged axons. PTEN is also important in surveillance and defense against unwanted cell growth, including protection from cancer. However, until now the development of inhibitors to promote axon regeneration have focused on methods that permanently silence PTEN.

Read more at: https://www.businesswire.com/news/home/20210608005831/en/BioAxone-BioSciences-Announces-Notice-of-Allowance-for-Self-Delivering-RNA-Interference-for-the-Treatment-of-Spinal-Cord-Injury

Leave a Reply

Your email address will not be published. Required fields are marked *

Font Resize